Figure 2. Proportion of patients receiving cinacalcet continuously over the study period, stratified by baseline iPTH category.

The proportion of patients receiving cinacalcet continuously is shown for 3 categories of serum iPTH at baseline (n = 624 for <300 pg/ml, n = 420 for 300–<500 pg/ml, and n = 340 for ≥500 pg/ml). Those 3 groups did not differ (P = 0.23 by log-rank test). Three months after the first prescription was the first visit at which patients were considered to be receiving cinacalcet, because the time between visits was 3 months. Data were derived from the subcohort (n = 1,384). The number of patients analyzed gradually decreased, and it was 313 at the 36th month after the first prescription, due to the end of follow-up, death, loss to follow-up, and other reasons.